p53 signaling in cancer progression and therapy

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• The p53 protein, a critical "guardian of the genome," preserves genomic integrity.
• Mutations in the TP53 gene occur in about 50% of human cancers, affecting breast, colon, lung, liver, prostate, bladder, and skin.
• Wild-type p53 halts the cell cycle upon DNA damage, preventing replication of damaged DNA.

Purpose of the Study:

• To review the molecular pathways through which mutant p53 proteins exert oncogenic activities.
• To explore prospective cancer treatment strategies focused on restoring wild-type p53 tumor-suppressive functions.

Main Methods:

• Literature review of studies on p53 protein function, mutations, and cancer.
• Analysis of molecular mechanisms underlying mutant p53 oncogenesis.
• Discussion of therapeutic strategies targeting p53.

Main Results:

• Mutant p53 proteins often gain oncogenic functions, promoting cancer cell proliferation, apoptosis evasion, invasion, and metastasis.
• Tumor-associated p53 mutations are linked to distinct phenotypes compared to loss of wild-type p53 function.
• p53 deficiency is a common hallmark of human cancer, presenting a significant therapeutic target.

Conclusions:

• Understanding mutant p53's oncogenic pathways is crucial for developing effective cancer treatments.
• Restoring wild-type p53 tumor suppressive functions offers a promising therapeutic avenue for various cancers.
• Targeting p53 represents a vital strategy in the fight against cancer due to its frequent mutation in malignancies.